Schubart Jane R, Schaefer Eric, Janicki Piotr, Adhikary Sanjib D, Schilling Amber, Hakim Alan J, Bascom Rebecca, Francomano Clair A, Raj Satish R
Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Department of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, PA, USA.
J Dent Anesth Pain Med. 2019 Oct;19(5):261-270. doi: 10.17245/jdapm.2019.19.5.261. Epub 2019 Oct 30.
People with the Ehlers-Danlos Syndromes (EDS), a group of heritable disorders of connective tissue, often report experiencing dental procedure pain despite local anesthetic (LA) use. Clinicians have been uncertain how to interpret this apparent LA resistance, as comparison of EDS and non-EDS patient experience is limited to anecdotal evidence and small case series. The primary goal of this hypothesis-generating study was to investigate the recalled adequacy of pain prevention with LA administered during dental procedures in a large cohort of people with and without EDS. A secondary exploratory aim asked people with EDS to recall comparative LA experiences.
We administered an online survey through various social media platforms to people with EDS and their friends without EDS, asking about past dental procedures, LA exposures, and the adequacy of procedure pain prevention. Among EDS respondents who both received LA and recalled the specific LA used, we compared agent-specific pain prevention for lidocaine, procaine, bupivacaine, mepivacaine, and articaine.
Among the 980 EDS respondents who had undergone a dental procedure LA, 88% (n = 860) recalled inadequate pain prevention. Among 249 non EDS respondents only 33% (n = 83) recalled inadequate pain prevention (P < 0.001 compared to EDS respondents). The agent with the highest EDS-respondent reported success rate was articaine (30%), followed by bupivacaine (25%), and mepivacaine (22%).
EDS survey respondents reported nearly three times the rate of LA non-response compared to non-EDS respondents, suggesting that LAs were less effective in preventing their pain associated with routine office dental procedures.
埃勒斯-当洛综合征(EDS)患者患有一组遗传性结缔组织疾病,尽管使用了局部麻醉剂(LA),但他们在牙科手术时仍常报告感到疼痛。临床医生一直不确定如何解读这种明显的局部麻醉抵抗现象,因为对EDS患者和非EDS患者经历的比较仅限于轶事证据和小病例系列。这项探索性研究的主要目的是调查一大群有或没有EDS的人在牙科手术中使用LA预防疼痛的回忆充足率。第二个探索性目标是询问EDS患者回忆比较局部麻醉的经历。
我们通过各种社交媒体平台对EDS患者及其没有EDS的朋友进行了一项在线调查,询问他们过去的牙科手术、局部麻醉暴露情况以及手术疼痛预防的充足性。在既接受过局部麻醉又能回忆起所使用的特定局部麻醉剂的EDS受访者中,我们比较了利多卡因、普鲁卡因、布比卡因、甲哌卡因和阿替卡因的特定药物疼痛预防效果。
在980名接受过牙科手术局部麻醉的EDS受访者中,88%(n = 860)回忆起疼痛预防不足。在249名非EDS受访者中,只有33%(n = 83)回忆起疼痛预防不足(与EDS受访者相比,P < 0.001)。EDS受访者报告成功率最高的药物是阿替卡因(30%),其次是布比卡因(25%)和甲哌卡因(22%)。
与非EDS受访者相比,EDS调查受访者报告的局部麻醉无反应率几乎是其三倍,这表明局部麻醉在预防他们与常规口腔牙科手术相关的疼痛方面效果较差。